Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.32 |
| ▸ | CDC25B | P30305 | 6/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23278056 | 0.90 | HSPA5 (0.32) | HSPA5PTPN1CDC25BPDE2ABCHE | |
| SCHEMBL2374198 | 0.87 | HSPA5 (0.35) | HSPA5PDE2ABCHE | |
| SCHEMBL12243232 | 0.87 | HSPA5 (0.35) | HSPA5PDE2ABCHE | |
| SCHEMBL19997429 | 0.87 | HSPA5 (0.35) | HSPA5PDE2ABCHE | |
| SCHEMBL10082719 | 0.86 | HSPA5 (0.36) | HSPA5PTPN1CDC25BPDE2ABCHE | |
| SCHEMBL19088037 | 0.86 | HSPA5 (0.36) | HSPA5PTPN1CDC25BPDE2ABCHE | |
| SCHEMBL12393393 | 0.86 | HSPA5 (0.36) | HSPA5PTPN1CDC25BPDE2ABCHE | |
| SCHEMBL10142704 | 0.84 | PDE9A (0.32) | PTPN1CDC25BBCHE | |
| SCHEMBL12393241 | 0.81 | HSPA5 (0.34) | HSPA5PDE2A | |
| SCHEMBL12068855 | 0.80 | TAAR1 (0.32) | HSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2937350-A1 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2268642-B1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8853171-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853171-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2576534-B1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318682-B2 | 1′substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011150288-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130034521-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | HSPA5 2596/4885PTPN1 317/4885CDC25B 1492/4885 |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | HSPA5 4044/4885PTPN1 271/4885CDC25B 551/4885 |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | HSPA5 2596/4885PTPN1 317/4885CDC25B 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.